The prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer

Allensworth, S.K.; Dowdy, Sean C.; Martin, John R.; Lemens, Maureen A.; McGree, M.; Weaver, Amy L.; Podratz, Karl C.; Bakkum-Gamez, Jamie N.

doi:10.1016/j.ygyno.2012.07.049

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have shown that thrombocytosis is associated with advanced FIGO stage and worse prognosis in patients with OC [123233]. These results were further confirmed in this study.…”

Section: Discussionsupporting

confidence: 90%

Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Cheng

et al. 2019

J Gynecol Oncol

View full text Add to dashboard Cite

ObjectiveTo investigate the association between pre-treatment thrombocytosis and prognosis in patients with ovarian cancer (OC).MethodsPubMed, EMBASE, and the Cochrane Library were searched for articles regarding the prognosis of OC patients with pre-treatment thrombocytosis by the end of March 2018. Pooled estimates for overall survival (OS) and progression-free survival (PFS) events were calculated as hazard ratios (HRs) either on a fixed or random effect model by Stata 13.0 software. Funnel plot and Egger's test were applied to evaluate publication bias and sensitivity analyses were undertaken to estimate the strength of outcomes.ResultsEleven studies that met the inclusion criteria were enrolled, including a total of 4,953 patients. Pooled results showed that pre-treatment thrombocytosis was significantly associated with OS (HR=1.722; 95% confidence interval [CI]=1.437–2.064) and PFS (HR=1.452; 95% CI=1.323–1.593) in the cohort. Significant correlation was found in OS and PFS between pre-treatment thrombocytosis and both epithelial OC (all stages and differentiation degrees of OC) and advanced epithelial OC (III or IV) by subgroup analyses, which were performed according to publication year, country, case numbers, OC category, International Federation of Gynecology and Obstetrics stage, and cut-off value. However, subgroup analyses indicated no significant correlation between pre-treatment thrombocytosis and OS for patients with high-grade serous (poorly differentiated or undifferentiated) OC (HR=1.220; 95% CI=0.946–1.573; p=0.125). Egger's test demonstrated no obvious publication bias in the articles enrolled in this study (OS: p=0.226; PFS: p=0.071).ConclusionPre-treatment thrombocytosis might be taken as an independent prognostic indicator for patients with OC.

show abstract

“…Several studies have shown that thrombocytosis is associated with advanced FIGO stage and worse prognosis in patients with OC [123233]. These results were further confirmed in this study.…”

Section: Discussionsupporting

confidence: 90%

Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Cheng

et al. 2019

J Gynecol Oncol

View full text Add to dashboard Cite

show abstract

“…The fact that there is fluctuation of platelet count during the course of primary treatment suggests its role in prediction of tumor recurrence and dependence of tumor progression. Moreover, it have been found that at the time of disease recurrence, an increased platelet count is present and was confirmed by our observations [9,19,20].Platelet count is probably directly dependent on the amount of tumor cells [9]and bone marrow may be adversely affected by adjuvant chemotherapy as a result of which patients may be less likely to genrate thrombocytosis in the setting of post-treatment.…”

Section: Discussionsupporting

confidence: 87%

“…Previous studies from different patient cohorts have showed that elevated platelet is a poor prognostic factor [9,19].Here we have demonstrated through a cohort of patients with disease recurrence that elevated platelet count before treatment is associated with shortened interval to progression and decreased overall survival, but elevated plasma D-dimer and fibrinogen level were not found to be significant, independent prognostic marker for recurrentepithelial ovarian cancer by univariate and multivariate analyses. Interestingly, here we found with strong evidence that the percent of reduction of platelet level at the end of primary treatment is an independent predictive factor of treatment response and the inadequate reduction of the platelet count is associated with shortened interval to progression and decreased overall survival of the recurrentepithelial ovarian cancer.…”

Section: Discussionmentioning

confidence: 49%

Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer

Hada

Han

2020

Preprint

View full text Add to dashboard Cite

ObjectivesWe sought to determine the impact of pretreatment plasma platelet levels, dimerized plasmin fragment (D-dimer) and fibrinogen in recurrent epithelial ovarian cancer (EOC) and the impact of platelet levels on SKOV3 cell lines growth and responsiveness to chemotherapy. MethodsUnder approval of ethical committee, we identified 104 women with recurrent EOC who underwent treatment between January 2010 and February 2015. Reviewing clinical, laboratory, and pathologic records from this retrospective cohort, we analyzed the correlation between pretreatment plasma Ddimer, fibrinogen, platelet levels and clinicopathological parameters, progression free survival (PFS)and overall survival (OS). Inco-culture experiments human ovarian cancer SKOV3 cell lines were used to test the effect of platelet levels on tumor growth and responsiveness to docetaxel. ResultsOf the 104 recurrent EOC, thrombocytosis at diagnosis and the decrease of platelet count by less than 25% after primary therapy were associated with worse median progression free survival (P = 0.003;P = 0.021) and median overall survival (P = 0.009;P = 0.009).Mean platelet levels declined at the end of primary therapy(P < 0.001) and rose at recurrence(P = 0.007) a.In multivariate analysis, elevated platelet levels at primary therapy and the decrease of platelet count less than 25% after primary therapy were unfavorable prognostic factor for PFS( P = 0.022; P = 0.015) and OS(P = 0.013;P = 0.007)in recurrent EOC, but elevated plasma D-dimer and fibrinogen were not. In SKOV-3 ovarian cancer cell lines, suitable concentration platelet co-culture protected against apoptosis (P < 0.05). ConclusionsPlatelet count during treatment could be used as a biomarker used for monitoring the disease recurrence and predicting treatment response. And platelet with suitable concentration co-culture protected against apoptosis inSKOV3 cell line, which may explain clinical observations.

show abstract

“…11 Thrombocytosis has also been associated with decreased progression-free survival and overall survival as well as suboptimal cytoreduction, increased CA 125, increased ascites volume, later stage disease at diagnosis, and higher grade tumors. 4,12,13 The mechanisms underlying the association between thrombocytosis and leukocytosis and postoperative morbidity are likely multifactorial. Platelets fuel tumor growth and metastasis through a paracrine circuit leading to more aggressive cancer biology.…”

Section: Discussionmentioning

confidence: 99%

Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer

Barber

Boggess²,

Le³

et al. 2015

Obstetrics &Amp; Gynecology

View full text Add to dashboard Cite

show abstract

The prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer

Cited by 3 publications

References 0 publications

Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Association of pretreatment thrombocytosis with prognosis in ovarian cancer: a systematic review and meta-analysis

Platelet count as a biomarker for monitoring treatment response and disease recurrence in recurrent epithelial ovarian cancer

Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer

Contact Info

Product

Resources

About